Involvement of microRNAs in HER2 signaling and trastuzumab treatment
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Involvement of microRNAs in HER2 signaling and trastuzumab treatment
Authors
Keywords
MicroRNA, HER2, Trastuzumab
Journal
TUMOR BIOLOGY
Volume 37, Issue 12, Pages 15437-15446
Publisher
Springer Nature
Online
2016-10-12
DOI
10.1007/s13277-016-5405-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- An overview of microRNAs
- (2015) Scott M. Hammond ADVANCED DRUG DELIVERY REVIEWS
- Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors
- (2015) Huiyuan Wang et al. ADVANCED DRUG DELIVERY REVIEWS
- CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells
- (2015) Delphine R. Boulbes et al. BREAST CANCER RESEARCH AND TREATMENT
- MicroRNA signatures highlight new breast cancer subtypes
- (2015) Malay Bhattacharyya et al. GENE
- Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer
- (2015) S. Yagishita et al. MOLECULAR CANCER THERAPEUTICS
- miR-331-3p inhibits proliferation and promotes apoptosis by targeting HER2 through the PI3K/Akt and ERK1/2 pathways in colorectal cancer
- (2015) DONGLI ZHAO et al. ONCOLOGY REPORTS
- miRNA-542-3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation
- (2015) TAO MA et al. ONCOLOGY REPORTS
- MicroRNA-based therapy and breast cancer: A comprehensive review of novel therapeutic strategies from diagnosis to treatment
- (2015) Parham Jabbarzadeh Kaboli et al. PHARMACOLOGICAL RESEARCH
- Impairment of growth of gastric carcinoma by miR-133-mediated Her-2 inhibition
- (2015) Xiao-Tao Zhang et al. TUMOR BIOLOGY
- miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance
- (2015) A De Cola et al. Cell Death & Disease
- MiRNA-101 inhibits breast cancer growth and metastasis by targeting CX chemokine receptor 7
- (2015) Jun-Tang Li et al. Oncotarget
- MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients
- (2015) Leticia De Mattos-Arruda et al. Oncotarget
- MicroRNAs: New Biomarkers for Diagnosis, Prognosis, Therapy Prediction and Therapeutic Tools for Breast Cancer
- (2015) Gloria Bertoli et al. Theranostics
- Role of erbB3 receptors in cancer therapeutic resistance
- (2014) Y. Lee et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN
- (2014) Xingming Ye et al. BMB Reports
- Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R
- (2014) Xing-Ming Ye et al. BMC CANCER
- Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial
- (2014) Volkmar Müller et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting HER3 with miR-450b-3p suppresses breast cancer cells proliferation
- (2014) Zhen Zhao et al. CANCER BIOLOGY & THERAPY
- Loss of Estrogen-Regulated microRNA Expression Increases HER2 Signaling and Is Prognostic of Poor Outcome in Luminal Breast Cancer
- (2014) S. T. Bailey et al. CANCER RESEARCH
- A Novel MAPK-microRNA Signature Is Predictive of Hormone-Therapy Resistance and Poor Outcome in ER-Positive Breast Cancer
- (2014) P. C. Miller et al. CLINICAL CANCER RESEARCH
- The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway
- (2014) Kojiro Eto et al. INTERNATIONAL JOURNAL OF CANCER
- MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer
- (2014) Wen-Dong Bai et al. INTERNATIONAL JOURNAL OF CANCER
- Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer
- (2014) Xiang-hua Liu et al. Molecular Cancer
- Therapeutic targeting of microRNAs: current status and future challenges
- (2014) Zhonghan Li et al. NATURE REVIEWS DRUG DISCOVERY
- MicroRNA-7 Inhibits Multiple Oncogenic Pathways to Suppress HER2Δ16 Mediated Breast Tumorigenesis and Reverse Trastuzumab Resistance
- (2014) Felicia C. Huynh et al. PLoS One
- miR-375 inhibits the proliferation of gastric cancer cells by repressing ERBB2 expression
- (2014) ZHI-YONG SHEN et al. Experimental and Therapeutic Medicine
- Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling
- (2014) Xiaofeng Dai et al. Scientific Reports
- miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer
- (2014) Boye Schnack Nielsen et al. Frontiers in Oncology
- The MicroRNA-21/PTEN Pathway Regulates the Sensitivity of HER2-Positive Gastric Cancer Cells to Trastuzumab
- (2013) Kojiro Eto et al. ANNALS OF SURGICAL ONCOLOGY
- Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
- (2013) Y H Park et al. BRITISH JOURNAL OF CANCER
- miRNA Dysregulation in Breast Cancer
- (2013) L. Mulrane et al. CANCER RESEARCH
- MiR-199b-5p targets HER2 in breast cancer cells
- (2013) Chen Fang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- MicroRNA-125b down-regulation mediates endometrial cancer invasion by targeting ERBB2
- (2013) Chao Shang et al. MEDICAL SCIENCE MONITOR
- Functional cooperation of miR-125a, miR-125b and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells
- (2013) S Wang et al. Cell Death & Disease
- Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours
- (2012) Brigid C. Browne et al. BREAST CANCER RESEARCH AND TREATMENT
- Increased signalling of EGFR and IGF1R and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas
- (2012) A Gallardo et al. BRITISH JOURNAL OF CANCER
- ZNF217 Is a Marker of Poor Prognosis in Breast Cancer That Drives Epithelial-Mesenchymal Transition and Invasion
- (2012) J. A. Vendrell et al. CANCER RESEARCH
- Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
- (2012) S. Chandarlapaty et al. CLINICAL CANCER RESEARCH
- Reactive oxygen species regulate ERBB2 and ERBB3 expression via miR-199a/125b and DNA methylation
- (2012) Jun He et al. EMBO REPORTS
- Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells
- (2012) Takehiro Ichikawa et al. PLoS One
- Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer
- (2012) Xiao-Feng Le et al. PLoS One
- rs12976445 variant in the pri-miR-125a correlates with a lower level of hsa-miR-125a and ERBB2 overexpression in breast cancer patients
- (2012) TOMASZ P. LEHMANN et al. Oncology Letters
- Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients
- (2011) Eun-Jung Jung et al. CANCER
- MicroRNA-125a-5p Is an Independent Prognostic Factor in Gastric Cancer and Inhibits the Proliferation of Human Gastric Cancer Cells in Combination with Trastuzumab
- (2011) N. Nishida et al. CLINICAL CANCER RESEARCH
- Developing therapeutic microRNAs for cancer
- (2011) A G Bader et al. GENE THERAPY
- The RNA-binding Protein HuR Opposes the Repression ofERBB-2Gene Expression by MicroRNA miR-331-3p in Prostate Cancer Cells
- (2011) Michael R. Epis et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Up-regulation ofmiR-21Mediates Resistance to Trastuzumab Therapy for Breast Cancer
- (2011) Chang Gong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PTEN, PIK3CA, p-AKT, and p-p70S6K Status
- (2010) Francisco J. Esteva et al. AMERICAN JOURNAL OF PATHOLOGY
- Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells
- (2010) B. C. Browne et al. ANNALS OF ONCOLOGY
- The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer
- (2010) Carlos A. Castaneda et al. CANCER AND METASTASIS REVIEWS
- Heterotrimerization of the Growth Factor Receptors erbB2, erbB3, and Insulin-like Growth Factor-I Receptor in Breast Cancer Cells Resistant to Herceptin
- (2010) X. Huang et al. CANCER RESEARCH
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
- (2010) N. A. O'Brien et al. MOLECULAR CANCER THERAPEUTICS
- The widespread regulation of microRNA biogenesis, function and decay
- (2010) Jacek Krol et al. NATURE REVIEWS GENETICS
- The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells
- (2010) J Dhillon et al. ONCOGENE
- Preliminary validation of ERBB2 expression regulated by miR-548d-3p and miR-559
- (2009) Hong Chen et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- miR-331-3p Regulates ERBB-2 Expression and Androgen Receptor Signaling in Prostate Cancer
- (2009) Michael R. Epis et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial
- (2009) Marc Spielmann et al. JOURNAL OF CLINICAL ONCOLOGY
- An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance
- (2009) D. Mitra et al. MOLECULAR CANCER THERAPEUTICS
- Cross-Talk Between the ErbB/HER Family and the Type I Insulin-Like Growth Factor Receptor Signaling Pathway in Breast Cancer
- (2008) Quanri Jin et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- Transforming Growth Factor Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab
- (2008) S. E. Wang et al. MOLECULAR AND CELLULAR BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started